Looking beyond Wall Street's top -and-bottom-line estimate forecasts for DexCom (DXCM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
DexCom Q1 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws.
23 Apr 2025 Date | | - Cons. EPS | - EPS |
6 Feb 2025 Date | | 0.52 Cons. EPS | 0.45 EPS |
24 Oct 2024 Date | | 0.44 Cons. EPS | 0.45 EPS |
25 Jul 2024 Date | | 0.39 Cons. EPS | 0.43 EPS |
5 Jun 2024 Date | | 0.27 Cons. EPS | 0.32 EPS |
23 Apr 2025 Date | | - Cons. EPS | - EPS |
6 Feb 2025 Date | | 0.52 Cons. EPS | 0.45 EPS |
24 Oct 2024 Date | | 0.44 Cons. EPS | 0.45 EPS |
25 Jul 2024 Date | | 0.39 Cons. EPS | 0.43 EPS |
5 Jun 2024 Date | | 0.27 Cons. EPS | 0.32 EPS |
Medical Devices Industry | Healthcare Sector | Mr. Kevin Ronald Sayer CEO | NASDAQ (NGS) Exchange | US2521311074 ISIN |
Germany Country | - Employees | - Last Dividend | 13 Jun 2022 Last Split | 14 Apr 2005 IPO Date |
DexCom, Inc. is an innovative medical device company with a strong focus on the design, development, and commercialization of continuous glucose monitoring (CGM) systems. Founded in 1999 and based in San Diego, California, DexCom has made significant strides in providing state-of-the-art diabetes management solutions. Their products cater to both individuals with diabetes and healthcare providers, offering advanced technology for continuous glucose tracking both in the United States and internationally. Through strategic collaborations, including agreements with Verily Life Sciences LLC and Verily Ireland Limited, DexCom continues to pioneer in the pursuit of enhancing diabetes care with the aim of developing new glucose monitoring products. The company's approach to directly market its innovations to endocrinologists, physicians, and diabetes educators underscores their commitment to integrating their systems into the healthcare community, thereby ensuring they meet the needs of their end-users effectively.